Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...
Lee’s Pharmaceutical
Unicycive Therapeutics Licenses Renazorb to Lee’s Pharma for Asian Markets
U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s...
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...
Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s
Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...
Lee’s Pharmaceutical Wins NMPA Approval for ALS Drug Teglutik
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has announced receiving market approval from the National...